Derleme
Yıl 2016,
Cilt: 8 Sayı: 6, 10 - 17, 08.11.2016
Öz
Abstract
Hematopoetic stem cell transplantation has been established as a curative treatment in children with malign and non-malign diseases. The first bone marrow transplant was done in a child by D Thomas at 1957. After the discovery of the human leukocyte antigens (HLAs) matching between patient and donor became possible leading to increased transplantation success. After that, the number of bone marrow transplants performed worldwide increased substantially. Now, it is accepted as a final treatment modality for many diseases in children, including hematologic malignancies, immundeficiencies, hemoglobinopathies, bone marrow failure syndromes and congenital metabolic disorders.
Anahtar Kelimeler
Kaynakça
- Kaynaklar 1.Sureda A, Bader P, Cesaro S, et al. Indications for allo- andauto-SCT for haematological diseases, solid tumours and im-mune disorders: current practice in Europe, 2015. Bone Mar-row Transplant 2015; 50 (8): 1037-56. 2.Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusionof bone marrow in patients receiving radiation and chemot-herapy. N Engl J Med 1957; 257: 491-96. 3.Buckley RH, Lucas ZJ, Hattler BG, et al. Defective cellularimmunity associated with chronic mucocutaneous moniliasisand recurrent staphylococcal botryomycosis: immunologicalreconstitution by allogeneic bone marrow. Clin Exp Immunol1968; 3 (2): 153-69. 4.Bach FH, Albertini RJ, Joo P, et al. Bone marrow transplan-tation in a patient with Wiskott-Aldrich syndrome. Lancet 1968;2 (7583): 1364-66. 5.Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE,Schultz KR. Use of G-CSF in matched sibling donor pediat-ric allogeneic transplantation: a consensus statement from theChildren’s Oncology Group (COG) Transplant DisciplineCommittee and Pediatric Blood and Marrow Transplant Con-sortium (PBMTC) Executive Committee. Pediatr Blood Can-cer 2006; 46 (4): 414-21. 6.Yesilipek MA, Hazar V, Küpesiz A, Kizilörs A, Uguz A, YeginO. Peripheral blood stem cell transplantation in children withbeta-thalassemia. Bone Marrow Transplant 2001; 28 (11):1037-40. 7.Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and effi-cacy of allogeneic PBSC collection in normal pediatric do-nors: the pediatric blood and marrow transplant consortiumexperience (PBMTC) 1996-2003. Bone Marrow Transplant2005; 35 (4): 361-67. 8.Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing therisks of G-CSF administration, leukopheresis, and standardmarrow harvest: ethical and safety considerations for normalpediatric hematopoietic cell donors. Pediatr Blood Cancer2006; 46 (4): 422-33. 9.Rocha V, Gluckman E. Eurocord-Netcord registry and Euro-pean Blood and Marrow Transplant group. Improving outco-mes of cord blood transplantation: HLA matching, cell doseand other graft- and transplantation-related factors. Br J Hae-matol 2009; 147 (2): 262-74. 10.Brunstein CG, Weisdorf DJ. Future of cord blood for onco-logy uses. Bone Marrow Transplant 2009; (44): 699-707. 11.Kögler G, Critser P, Trapp T, Yoder M. Future of cord blo-od for non-oncology uses. Bone Marrow Transplant 2009; (44):683-97. 12.Yeşilipek MA. Çocuklarda hematopoetik kök hücre nakli. TürkPed Arş 2014; 49: 91-98. 13.Gratwohl A. Principals of conditioning. In: Apperly J, Car-reras E, Gluckman E Grawthol A, Masszi T, (eds). Hemato-poetic Stem Cell Transplantation, The EBMT Handbook. Eu-ropean School of Hematology, 2008: 128-44. 14.Kansoy S. Çocukluk çağı solid tümörlerinde HKH naklinin yeri.9. Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Teda-vileri Kongresi, 3-5 Mart 2016, Antalya, s: 32-34. 15.Majhail NS, Farnia SH, Carpenter PA, et al. Indications forautologous and allogeneic hematopoietic cell transplantati-on: Guidelines from the American Society for Blood and Mar-row Transplantation. Biol Blood Marrow Transplant 2015;21 (11): 1863-69. 16.Indications for HSCT in Children- UK Paediatric BMT Gro-up 2015, UK Paediatric BMT Group HSCT Indications, 15 Oc-tober 2015. 17.Sureda A, Bader P, Cesaro S, et al. Indications for allo- andauto-SCT for haematological diseases, solid tumours and im-mune disorders: current practice in Europe, 2015. Bone Mar-row Transplant 2015; 50 (8): 1037-56. 18.Nucci M, Andrade F, Vigorito A, et al. Infectious complica-tions in patients randomized to receive allogeneic bone mar-row or peripheral blood transplantation. Transpl Infect Dis2003; 5: 167-73. 19.Eapen M, Horowitz MM, Klein JP, et al. Higher mortality af-ter allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompa-tibility and Alternate Stem Cell Source Working Committeeof the International Bone Marrow Transplant Registry. J ClinOncol 2004; 22: 4872-80. 20.Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, An-tin JH. Acute and chronic graft-versus-host disease after alloge-neic peripheral blood stem-cell and bone marrow transplantati-on: a meta-analysis. J Clin Oncol 2001; 19: 3685-91. 21.Rizzo JD, Wingard JR, Tichelli A, et al. Recommended scree-ning and preventive practices for long-term survivors after hae-matopoietic cell transplantation: joint recommendations of theEuropean Group for Blood and Marrow Transplantation, Cen-tre for International, Blood and Marrow Transplant Research,and the American Society for Blood and Marrow Transplan-tation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant2006; 37: 249-61. 22.Cohen A, Békássy AN, Gaiero A, et al. Endocrinological latecomplications after hematopoietic SCT in children. Bone Mar-row Transplant 2008; 41 (Suppl 2): S43-48. 23.Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Ro-bison LL. New malignancies after blood or marrow stem-celltransplantation in children and adults: incidence and risk fac-tors. J Clin Oncol 2003; 21: 1352-58. 24.Dietz AC, Duncan CN, Alter BP, et al. The Second PediatricBlood and Marrow Transplant Consortium International Con-sensus Conference on Late Effects after Pediatric Hematopo-ietic Cell Transplantation (HCT): Defining the Unique LateEffects of Children Undergoing HCT for Immune Deficienci-es, Inherited Marrow Failure Disorders, and Hemoglobino-pathies. Biol Blood Marrow Transplant 2016: S1083-8791 (16)30396-2.
Yıl 2016,
Cilt: 8 Sayı: 6, 10 - 17, 08.11.2016
Öz
Öz
Hematopoietik kök hücre nakli malin ve malin olmayan hastalığı olan çocuklarda iyileştirici bir tedavi yöntemi olarak kabul edilmektedir. İlk kemik iliği nakli 1957yılında D Thomas tarafından yapılmıştır. HLA gruplarının tanımlanması ve kullanılmasından sonra transplantasyon başarısı artmış ve daha yaygın kullanılmaya başlanmıştır. Bugün hematolojik malignite, immün yetmezlik, hemoglobinopati, kemik iliği yetmezlikleri ve doğuştan metabolizma hastalıklarında son tedavi modeli olarak kullanılmaktadır.
Anahtar Kelimeler
Kaynakça
- Kaynaklar 1.Sureda A, Bader P, Cesaro S, et al. Indications for allo- andauto-SCT for haematological diseases, solid tumours and im-mune disorders: current practice in Europe, 2015. Bone Mar-row Transplant 2015; 50 (8): 1037-56. 2.Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusionof bone marrow in patients receiving radiation and chemot-herapy. N Engl J Med 1957; 257: 491-96. 3.Buckley RH, Lucas ZJ, Hattler BG, et al. Defective cellularimmunity associated with chronic mucocutaneous moniliasisand recurrent staphylococcal botryomycosis: immunologicalreconstitution by allogeneic bone marrow. Clin Exp Immunol1968; 3 (2): 153-69. 4.Bach FH, Albertini RJ, Joo P, et al. Bone marrow transplan-tation in a patient with Wiskott-Aldrich syndrome. Lancet 1968;2 (7583): 1364-66. 5.Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE,Schultz KR. Use of G-CSF in matched sibling donor pediat-ric allogeneic transplantation: a consensus statement from theChildren’s Oncology Group (COG) Transplant DisciplineCommittee and Pediatric Blood and Marrow Transplant Con-sortium (PBMTC) Executive Committee. Pediatr Blood Can-cer 2006; 46 (4): 414-21. 6.Yesilipek MA, Hazar V, Küpesiz A, Kizilörs A, Uguz A, YeginO. Peripheral blood stem cell transplantation in children withbeta-thalassemia. Bone Marrow Transplant 2001; 28 (11):1037-40. 7.Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and effi-cacy of allogeneic PBSC collection in normal pediatric do-nors: the pediatric blood and marrow transplant consortiumexperience (PBMTC) 1996-2003. Bone Marrow Transplant2005; 35 (4): 361-67. 8.Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing therisks of G-CSF administration, leukopheresis, and standardmarrow harvest: ethical and safety considerations for normalpediatric hematopoietic cell donors. Pediatr Blood Cancer2006; 46 (4): 422-33. 9.Rocha V, Gluckman E. Eurocord-Netcord registry and Euro-pean Blood and Marrow Transplant group. Improving outco-mes of cord blood transplantation: HLA matching, cell doseand other graft- and transplantation-related factors. Br J Hae-matol 2009; 147 (2): 262-74. 10.Brunstein CG, Weisdorf DJ. Future of cord blood for onco-logy uses. Bone Marrow Transplant 2009; (44): 699-707. 11.Kögler G, Critser P, Trapp T, Yoder M. Future of cord blo-od for non-oncology uses. Bone Marrow Transplant 2009; (44):683-97. 12.Yeşilipek MA. Çocuklarda hematopoetik kök hücre nakli. TürkPed Arş 2014; 49: 91-98. 13.Gratwohl A. Principals of conditioning. In: Apperly J, Car-reras E, Gluckman E Grawthol A, Masszi T, (eds). Hemato-poetic Stem Cell Transplantation, The EBMT Handbook. Eu-ropean School of Hematology, 2008: 128-44. 14.Kansoy S. Çocukluk çağı solid tümörlerinde HKH naklinin yeri.9. Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Teda-vileri Kongresi, 3-5 Mart 2016, Antalya, s: 32-34. 15.Majhail NS, Farnia SH, Carpenter PA, et al. Indications forautologous and allogeneic hematopoietic cell transplantati-on: Guidelines from the American Society for Blood and Mar-row Transplantation. Biol Blood Marrow Transplant 2015;21 (11): 1863-69. 16.Indications for HSCT in Children- UK Paediatric BMT Gro-up 2015, UK Paediatric BMT Group HSCT Indications, 15 Oc-tober 2015. 17.Sureda A, Bader P, Cesaro S, et al. Indications for allo- andauto-SCT for haematological diseases, solid tumours and im-mune disorders: current practice in Europe, 2015. Bone Mar-row Transplant 2015; 50 (8): 1037-56. 18.Nucci M, Andrade F, Vigorito A, et al. Infectious complica-tions in patients randomized to receive allogeneic bone mar-row or peripheral blood transplantation. Transpl Infect Dis2003; 5: 167-73. 19.Eapen M, Horowitz MM, Klein JP, et al. Higher mortality af-ter allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompa-tibility and Alternate Stem Cell Source Working Committeeof the International Bone Marrow Transplant Registry. J ClinOncol 2004; 22: 4872-80. 20.Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, An-tin JH. Acute and chronic graft-versus-host disease after alloge-neic peripheral blood stem-cell and bone marrow transplantati-on: a meta-analysis. J Clin Oncol 2001; 19: 3685-91. 21.Rizzo JD, Wingard JR, Tichelli A, et al. Recommended scree-ning and preventive practices for long-term survivors after hae-matopoietic cell transplantation: joint recommendations of theEuropean Group for Blood and Marrow Transplantation, Cen-tre for International, Blood and Marrow Transplant Research,and the American Society for Blood and Marrow Transplan-tation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant2006; 37: 249-61. 22.Cohen A, Békássy AN, Gaiero A, et al. Endocrinological latecomplications after hematopoietic SCT in children. Bone Mar-row Transplant 2008; 41 (Suppl 2): S43-48. 23.Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Ro-bison LL. New malignancies after blood or marrow stem-celltransplantation in children and adults: incidence and risk fac-tors. J Clin Oncol 2003; 21: 1352-58. 24.Dietz AC, Duncan CN, Alter BP, et al. The Second PediatricBlood and Marrow Transplant Consortium International Con-sensus Conference on Late Effects after Pediatric Hematopo-ietic Cell Transplantation (HCT): Defining the Unique LateEffects of Children Undergoing HCT for Immune Deficienci-es, Inherited Marrow Failure Disorders, and Hemoglobino-pathies. Biol Blood Marrow Transplant 2016: S1083-8791 (16)30396-2.
Toplam 1 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | makale |
| Yazarlar | |
| Yayımlanma Tarihi | 8 Kasım 2016 |
| Yayımlandığı Sayı | Yıl 2016 Cilt: 8 Sayı: 6 |
